Tizanidine hydrochloride capsule and preparation method thereof

By adjusting the composition and preparation technology of tizanidine hydrochloride capsules, the drug release characteristics and biocompatibility problems are solved, stable binding and efficient adhesion of the drug are achieved, and the bioavailability and stability of the drug are improved.

CN119157858APending Publication Date: 2024-12-20HANGZHOU HONGYOU PHARM TECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411383261.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-30
Publication Date
2024-12-20

AI Technical Summary

Technical Problem

The proportion of coating liquid components of existing tizanidine hydrochloride capsules affects the drug release characteristics and biocompatibility, resulting in unstable efficacy.

Method used

By adjusting the proportion of drug ingredients, coating ingredients and auxiliary materials, wet granulation and fluidized bed coating technology, the specific surface area and pore structure of the particles are improved, the contact area and adhesion between the drug and the coating liquid are enhanced, and the use of high Molecular materials and crosslinking agents improve the stability of the coating film.

Benefits of technology

Form more stable drug particles, improve the uniformity and stability of drugs, enhance the bioavailability and stability of drugs, reduce the reduction of drug efficacy, and ensure the stable existence of drugs in the body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_10
    Figure QLYQS_10
  • Figure QLYQS_13
    Figure QLYQS_13
  • Figure BDA0005070415460000031
    Figure BDA0005070415460000031
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and discloses a tizanidine hydrochloride capsule and a preparation method thereof, and the capsule is composed of a medicine component, a coating component and an auxiliary material. The particles are suitable for oral preparations, reasonable swallowing performance and absorbability can be guaranteed, the small particle size is beneficial for increasing the specific surface area of the particles, and therefore the contact area with a medicine coating solution is increased, the pore structure of the particles adsorbs and retains the coating solution, the adhesive force of tizanidine hydrochloride is improved, and the bioavailability of tizanidine hydrochloride is improved. The proper pore structure is beneficial to promoting the tizanidine hydrochloride to be firmly combined with the surfaces of the particles through physical interaction, and the beneficial effect that the tizanidine hydrochloride can be stably combined with the particles is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, in particular to a tizanidine hydrochloride capsule and a preparation method thereof. Background Art

[0002] Tizanidine hydrochloride, chemical name 5-chloro-N-(4,5-dihydro-1H-imidazole-2-yl)-2,1,3-benzothiadiazole-4-amine hydrochloride, is a central skeletal muscle relaxant with an imidazoline structure developed by Novartis, Switzerland. It was first launched in Denmark and Switzerland in 1988, and then successively obtained sales licenses in more than 20 countries including Europe, the United States, and Japan. my country's pharmaceutical manufacturers have successfully developed various specifications of tizanidine hydrochloride tablets (such as Kailaitong), and the human pharmacokinetics and relative bioavailability of domestic and imported tizanidine are almost the same. It is clinically used to treat diseases such as increased skeletal muscle tension, muscle spasms and myotonia caused by central injury. It has good effects on tension headaches, trigeminal neuralgia and myofascial pain syndrome. It can also be used as an adjuvant for general anesthesia or regional anesthesia, preoperative and postoperative sedatives, and postoperative analgesics. This product relieves spasticity without causing muscle weakness and does not produce psychological dependence at therapeutic doses. It is a central muscle relaxant with good tolerance and efficacy.

[0003] As prior art publication number is a kind of tizanidine hydrochloride capsule and preparation method thereof of CN 113081997 A, belong to the field of medical technology.Described tizanidine hydrochloride capsule utilizes tizanidine hydrochloride coating liquid to carry out coating preparation of drug-containing particles to blank pill core, and packs into hollow capsule and prepares, avoids interaction between medicines, improves the stability of preparation again, has important medical value.

[0004] Yet the dosage range of each component in the coating solution, hypromellose 10-20 weight portion, colloidal silicon dioxide 2-20 weight portion, can affect the release characteristics and the biocompatibility of the final preparation, and then cause tizanidine hydrochloride can not be combined with particle stability, have a strong impact on drug efficacy. Summary of the invention

[0005] 1. Technical issues to be resolved

[0006] In view of the deficiencies in the prior art, the invention provides a tizanidine hydrochloride capsule and a preparation method thereof, which has the advantages of ensuring the stable existence of tizanidine hydrochloride, stably improving a tizanidine hydrochloride coating solution, and solving the problems of the above-mentioned technology.

[0007] Technical Solution

[0008] To achieve the above object, the present invention provides the following technical scheme: tizanidine hydrochloride capsule, wherein the capsule is composed of a pharmaceutical ingredient, a coating component and an auxiliary material, and the pharmaceutical ingredient comprises a mixed preparation of the following materials in a weight ratio:

[0009] Tizanidine hydrochloride 10%-15%;

[0010] The coating component is prepared by mixing the following materials in weight ratio:

[0011] Hydroxypropyl methylcellulose 15%-20%;

[0012] Polyvinyl alcohol 5%-10%;

[0013] Colloidal silicon dioxide 5%-8%;

[0014] The auxiliary material is prepared by mixing the following materials in weight ratio:

[0015] Polymethyl methacrylate 2%-5%;

[0016] Purified water 40%-63%;

[0017] Glycerin 3%-5%.

[0018] Preferably, 10% tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 15% hypromellose; 5% polyvinyl alcohol; 5% colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 2% polymethyl methacrylate; 63% purified water; and 5% glycerol.

[0019] Preferably, 15% of tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 15% of hypromellose; 10% of polyvinyl alcohol; 5% of colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 5% of polymethyl methacrylate; 45% of purified water; and 5% of glycerol.

[0020] Preferably, 12% of tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 17% of hypromellose; 9% of polyvinyl alcohol; 7% of colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 5% of polymethyl methacrylate; 47% of purified water; and 3% of glycerol.

[0021] A method for preparing tizanidine hydrochloride capsules, the method comprising the steps of:

[0022] Step 1, drug ingredient material preparation: tizanidine hydrochloride, solvent: select distilled water or ethanol, preliminary wet mixture;

[0023] Step 2, mixing tizanidine hydrochloride, polymethyl methacrylate, purified water and glycerol;

[0024] Step 3: Wet granulation: Use a wet granulator, set the spray pressure to 1-2 bar, liquid injection rate: 2-5 ml of liquid per minute, granulation time: continue for 30 minutes, until visible particles are formed;

[0025] Step 4: Preparation of coating ingredients: Prepare hydroxypropyl methylcellulose, polyvinyl alcohol, colloidal silicon dioxide and water in proportion, stir and disperse, heat water temperature: 40-60°C, stirring speed: 300-600rpm, continue for 20-30 minutes, use a viscometer with a target range of 200-500mPa·s to ensure it is suitable for spraying;

[0026] Step 5. Equipment preparation: fluidized bed coating machine, spray pressure: 1-3 bar, nozzle diameter: 0.7-1 mm,

[0027] Step 6: Spray coating: set to 3000-6000g / h, coating time lasts 60-90 minutes, check coating uniformity regularly, and observe particles every 20 minutes;

[0028] Step 7. Drying: Fluidized bed dryer temperature: set to 50°C, drying time: 50-70 minutes, cooling after drying, cooling time: 30 minutes, room temperature environment.

[0029] Preferably, the mixed expression in step 2 is:

[0030]

[0031] The actual mixing efficiency is:

[0032] Preferably, the spray pressure expression in step 3 is: 1bar≤P≤2bar;

[0033] The liquid injection speed is: 2ml / min≤Q≤5ml / min;

[0034] The granulation time expression is: T = 30 minutes;

[0035] The particle formation condition expression is: particle visibility = True;

[0036] Where: Q is the liquid injection speed, T is the granulation time.

[0037] Preferably, the heating water temperature in step 4 is expressed as: 40°C ≤ T w ≤60℃;

[0038] The stirring speed expression is: 300 rpm≤N≤600 rpm;

[0039] The duration expression is: 20 minutes ≤ t d ≤30 minutes;

[0040] Solution viscosity = μ = f(T w ,N,t d ,Element)

[0041] Where: μ is the viscosity of the solution, and f is a function that depends on the heating water temperature, stirring speed, duration, and composition.

[0042] Preferably, the spraying rate expression in step 6 is: 300g / h≤R≤600g / h;

[0043] The coating time expression is: 60 minutes ≤ t c ≤90 minutes;

[0044] Total coating amount = R × t c

[0045] Where: R represents the spraying rate in grams per hour; t c For coating time.

[0046] Compared with the prior art, the present invention provides tizanidine hydrochloride capsules and a preparation method thereof, which have the following beneficial effects:

[0047] 1, the present invention is by improving the specific surface area of ​​granule, thereby strengthens the contact area with drug coating liquid, contributes to form more stable combination, the granule formed by wet granulation has good fluidity and compressibility usually, enhances their uniformity and stability in preparation, the granule with good fluidity can cover coating liquid more evenly, improves the link effect with tizanidine hydrochloride, the pore structure adsorption of granule and retains coating liquid, and then improves the sticking power of tizanidine hydrochloride, suitable pore structure contributes to promote that tizanidine hydrochloride is firmly bonded to particle surface by physical interaction, reaches the beneficial effect that guarantees that tizanidine hydrochloride can be combined with particle stability.

[0048] 2, the present invention can strengthen the supporting force and the stability of particle by selecting suitable adjuvant, these adjuvants are chemically compatible with tizanidine hydrochloride, and can effectively prevent the degradation of medicine, ensure the bioavailability of medicine, coating solution adopts macromolecular materials such as hydroxypropyl methylcellulose, polyvinyl alcohol, these materials can not only keep stable in health, can also adsorb the surface of medicine, their chemical composition should ensure good compatibility with tizanidine hydrochloride, avoid the drug effect reduction that mutual reaction causes, in coating solution, may add an amount of plasticizer, to improve the pliability and the integrity of coating film, this helps to strengthen the adhesion ability of coating layer, reduce stripping phenomenon, ensure the stability of medicine, by Adjust the composition ratio and concentration of the coating solution to achieve ideal viscosity, suitable viscosity ensures that the coating solution can be evenly sprayed on the particle surface and fully penetrated, thereby improving adhesion and stability, control spray pressure and spray speed during spraying to ensure that the coating solution is evenly covered, while avoiding excessive liquid accumulation on the particle surface, delicate spraying technology can form a uniform coating layer, thereby enhancing the stability of the drug, consider introducing a cross-linking agent in the coating solution, to improve the stability and tolerance of the coating film, the application of the cross-linking agent strengthens the structure of the film, so that it is more firmly combined with the particles, and reaches the beneficial effect of improving the tizanidine hydrochloride coating solution to be able to stably link with the particles. DETAILED DESCRIPTION

[0049] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0050] Tizanidine hydrochloride capsule, described capsule is made up of pharmaceutical ingredient, coating component and auxiliary material, and described pharmaceutical ingredient comprises the mixed preparation of following material in weight ratio:

[0051] Tizanidine hydrochloride 10%-15%;

[0052] The coating component is prepared by mixing the following materials in weight ratio:

[0053] Hydroxypropyl methylcellulose 15%-20%;

[0054] Polyvinyl alcohol 5%-10%;

[0055] Colloidal silicon dioxide 5%-8%;

[0056] The auxiliary material is prepared by mixing the following materials in weight ratio:

[0057] Polymethyl methacrylate 2%-5%;

[0058] Purified water 40%-63%;

[0059] Glycerin 3%-5%.

[0060] Increasing the specific surface area of ​​the particles, thereby enhancing the contact area with the drug coating solution, helps to form a more stable bond.

[0061] Granules formed by wet granulation usually have good fluidity and compressibility, which enhances their uniformity and stability in the formulation. Granules with good fluidity can be more evenly covered with coating liquid, which improves the linking effect with tizanidine hydrochloride.

[0062] The pore structure of the particles adsorbs and retains the coating solution, thereby improving the adhesion of tizanidine hydrochloride. Suitable pore structure helps promote that tizanidine hydrochloride is firmly bonded to the particle surface through physical interaction.

[0063] A method for preparing tizanidine hydrochloride capsules, the method comprising the steps of:

[0064] Step 1, drug ingredient material preparation: tizanidine hydrochloride, solvent: select distilled water or ethanol, preliminary wet mixture;

[0065] Step 2, mixing tizanidine hydrochloride, polymethyl methacrylate, purified water and glycerol;

[0066] Step 3: Wet granulation: Use a wet granulator, set the spray pressure to 1-2 bar, liquid injection rate: 2-5 ml of liquid per minute, granulation time: continue for 30 minutes, until visible particles are formed;

[0067] Step 4: Preparation of coating ingredients: Prepare hydroxypropyl methylcellulose, polyvinyl alcohol, colloidal silicon dioxide and water in proportion, stir and disperse, heat water temperature: 40-60°C, stirring speed: 300-600rpm, continue for 20-30 minutes, use a viscometer with a target range of 200-500mPa·s to ensure it is suitable for spraying;

[0068] Step 5. Equipment preparation: fluidized bed coating machine, spray pressure: 1-3 bar, nozzle diameter: 0.7-1 mm,

[0069] Step 6: Spray coating: set to 3000-6000g / h, coating time lasts 60-90 minutes, check coating uniformity regularly, and observe particles every 20 minutes;

[0070] Step 7. Drying: Fluidized bed dryer temperature: set to 50°C, drying time: 50-70 minutes, cooling after drying, cooling time: 30 minutes, room temperature environment.

[0071] In the preparation of granules, selecting suitable auxiliary materials can enhance the supporting force and stability of granules. These auxiliary materials are chemically compatible with tizanidine hydrochloride and can effectively prevent the degradation of the drug, ensuring the bioavailability of the drug.

[0072] The coating liquid uses high molecular materials such as hydroxypropyl methylcellulose and polyvinyl alcohol, which can not only remain stable in the body, but also adsorb on the surface of the drug. Their chemical composition should ensure good compatibility with tizanidine hydrochloride to avoid reduced efficacy caused by mutual reaction.

[0073] An appropriate amount of plasticizer may be added to the coating solution to improve the flexibility and integrity of the coating film. This helps to enhance the adhesion of the coating layer, reduce peeling, and ensure a stable link between the drug and the particles.

[0074] Preferably, the mixed expression in step 2 is:

[0075]

[0076] The actual mixing efficiency is:

[0077] Preferably, the spray pressure expression in step 3 is: 1bar≤P≤2bar;

[0078] The liquid injection speed is: 2ml / min≤Q≤5ml / min;

[0079] The granulation time expression is: T = 30 minutes;

[0080] The particle formation condition expression is: particle visibility = True;

[0081] Where: Q is the liquid injection speed, T is the granulation time.

[0082] Preferably, the heating water temperature in step 4 is expressed as: 40°C ≤ T w ≤60℃;

[0083] The stirring speed expression is: 300rpm≤N≤600rpm;

[0084] The duration expression is: 20 minutes ≤ t d ≤30 minutes;

[0085] Solution viscosity = μ = f(T w ,N,t d ,Element)

[0086] Where: μ is the viscosity of the solution, and f is a function that depends on the heating water temperature, stirring speed, duration, and composition.

[0087] Preferably, the spraying rate expression in step 6 is: 300g / h≤R≤600g / h;

[0088] The coating time expression is: 60 minutes ≤ t c ≤90 minutes;

[0089] Total coating amount = R × t c

[0090] Where: R represents the spraying rate in grams per hour; t c For coating time.

[0091] The ideal viscosity is achieved by adjusting the composition ratio and concentration of the coating liquid. Appropriate viscosity ensures that the coating liquid can be evenly sprayed on the surface of the particles and fully penetrated, thereby improving adhesion and stability.

[0092] During the spraying process, the spray pressure and spray speed are controlled to ensure uniform coverage of the coating liquid while avoiding excessive liquid accumulation on the particle surface. The delicate spraying technology can form a uniform coating layer, thereby enhancing the stability of the drug.

[0093] Consider introducing a cross-linking agent into the coating solution to improve the stability and tolerance of the coating film. The application of the cross-linking agent strengthens the structure of the film and makes it more firmly bonded to the particles.

[0094] According to the difference of tizanidine hydrochloride used weight percent, adjust the raw material mass ratio in the specific embodiment.

[0095] Example 1

[0096] The invention discloses a coating composition comprising 10% tizanidine hydrochloride; the coating composition is prepared by mixing the following materials in weight ratio: 15% hypromellose; 5% polyvinyl alcohol; and 5% colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 2% polymethyl methacrylate; 63% purified water; and 5% glycerol.

[0097] Example 2

[0098] 15% of tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 15% of hypromellose; 10% of polyvinyl alcohol; 5% of colloidal silicon dioxide; the auxiliary material is prepared by mixing the following materials in weight ratio: 5% of polymethyl methacrylate; 45% of purified water; and 5% of glycerol.

[0099] Example 3

[0100] The invention discloses a coating composition comprising 12% tizanidine hydrochloride; the coating composition is prepared by mixing the following materials in weight ratio: 17% hydroxypropyl methylcellulose; 9% polyvinyl alcohol; and 7% colloidal silicon dioxide; and the auxiliary materials are prepared by mixing the following materials in weight ratio: 5% polymethyl methacrylate; 47% purified water; and 3% glycerol.

[0101] Comparative Example 1

[0102] Adopt the method for Example 1 in CN 113081997 A to prepare tizanidine hydrochloride capsules.

[0103] Comparative Example 2

[0104] The difference between this comparative example and Example 1 is that no polyvinyl alcohol is added to the coating composition.

[0105] Below the tizanidine hydrochloride capsules that embodiment 1-3 and comparative example 1-2 are processed are carried out dissolution (60min) detection and foreign matter content detection, and the result is as shown in table 1.

[0106] Table 1

[0107] Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 60min dissolution 101.79% 101.24% 100.98% 100.43% 98.57% Impurity content 0.44% 0.39% 0.48% 0.87% 0.69%

[0108] In addition the tizanidine hydrochloride capsules that embodiment 1-3 and comparative example 1-2 are made are stored in storage room (25 ℃, 50RH%) for one year, then carry out dissolution detection, the result is as shown in table 2.

[0109] Table 2

[0110] Example 1 Example 2 Example 3 Comparative Example 1 Comparative Example 2 60min dissolution 100.88% 100.64% 100.07% 97.27% 92.03%

[0111] As can be known from above-mentioned form, the tizanidine hydrochloride capsules prepared by embodiment 1-3 have high dissolution, low foreign matter content and high stability.

[0112] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and alterations may be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. Tizanidine hydrochloride capsule, it is characterized in that, The capsule is composed of a drug component, a coating component and excipients, and the drug component is prepared by mixing the following materials in the following weight ratios: Tizanidine hydrochloride 10%-15%; The coating component is prepared by mixing the following materials in weight ratio: Hydroxypropyl methylcellulose 15%-20%; Polyvinyl alcohol 5%-10%; Colloidal silicon dioxide 5%-8%; The auxiliary material is prepared by mixing the following materials in weight ratio: Polymethyl methacrylate 2%-5%; Purified water 40%-63%; Glycerin 3%-5%.

2. Tizanidine hydrochloride capsule according to claim 1, is characterized in that: 10% tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 15% hydroxypropyl methylcellulose; 5% polyvinyl alcohol; 5% colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 2% polymethyl methacrylate; 63% purified water; 5% glycerol.

3. tizanidine hydrochloride capsule according to claim 1, is characterized in that: 15% tizanidine hydrochloride; the coating component is prepared by mixing the following materials in weight ratio: 15% hydroxypropyl methylcellulose; 10% polyvinyl alcohol; 5% colloidal silicon dioxide; the auxiliary material is prepared by mixing the following materials in weight ratio: 5% polymethyl methacrylate; 45% purified water; 5% glycerol.

4. tizanidine hydrochloride capsule according to claim 1, is characterized in that: The coating component is prepared by mixing the following materials in weight ratio: 17% hydroxypropyl methylcellulose; 9% polyvinyl alcohol; 7% colloidal silicon dioxide; the auxiliary materials are prepared by mixing the following materials in weight ratio: 5% polymethyl methacrylate; 47% purified water; and 3% glycerol.

5. a method for preparing tizanidine hydrochloride capsules, characterized in that, The preparation method is used for the capsule according to claim 1, and the preparation method comprises the following steps: Step 1, drug ingredient material preparation: tizanidine hydrochloride, solvent: select distilled water or ethanol, preliminary wet mixture; Step 2, mixing tizanidine hydrochloride, polymethyl methacrylate, purified water and glycerol; Step 3: Wet granulation: Use a wet granulator, set the spray pressure to 1-2 bar, liquid injection rate: 2-5 ml of liquid per minute, granulation time: continue for 30 minutes, until visible particles are formed; Step 4: Preparation of coating ingredients: Prepare hydroxypropyl methylcellulose, polyvinyl alcohol, colloidal silicon dioxide and water in proportion, stir and disperse, heat water temperature: 40-60°C, stirring speed: 300-600rpm, continue for 20-30 minutes, use a viscometer with a target range of 200-500 mPa·s to ensure it is suitable for spraying; Step 5. Equipment preparation: fluidized bed coating machine, spray pressure: 1-3 bar, nozzle diameter: 0.7-1mm, Step 6: Spray coating: set to 3000-6000g / h, coating time lasts 60-90 minutes, check coating uniformity regularly, and observe particles every 20 minutes; Step 7. Drying: Fluidized bed dryer temperature: set to 50°C, drying time: 50-70 minutes, cooling after drying, cooling time: 30 minutes, room temperature environment.

6. the method for preparing tizanidine hydrochloride capsules according to claim 5, is characterized in that: The mixed expression in step 2 is: The actual mixing efficiency is: .

7. Tizanidine hydrochloride capsule preparation method according to claim 5, is characterized in that: The spray pressure expression in step 3 is: ; The liquid injection speed is: The granulation time expression is: The particle formation condition expression is: Where: Q is the liquid injection speed, T is the granulation time.

8. Tizanidine hydrochloride capsule preparation method according to claim 5, is characterized in that: The heating water temperature expression in step 4 is: ; The stirring speed expression is: ; The duration expression is: ; Where: μ is the viscosity of the solution, and f is a function that depends on the heating water temperature, stirring speed, duration, and composition.

9. the method for preparing tizanidine hydrochloride capsules according to claim 5, is characterized in that: The spraying rate expression in step 6 is: ; The coating time expression is: ; 10. Where: R represents the spraying rate in grams per hour; t c For coating time.

Citation Information

Patent Citations

  • Tizanidine hydrochloride capsule and preparation method thereof

    CN113081997A